NasdaqCM:ATHX

Stock Analysis Report

Executive Summary

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Athersys's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATHX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.3%

ATHX

0.7%

US Biotechs

0.2%

US Market


1 Year Return

-32.8%

ATHX

5.6%

US Biotechs

12.2%

US Market

Return vs Industry: ATHX underperformed the US Biotechs industry which returned 5.6% over the past year.

Return vs Market: ATHX underperformed the US Market which returned 12.2% over the past year.


Shareholder returns

ATHXIndustryMarket
7 Day6.3%0.7%0.2%
30 Day0%8.3%3.5%
90 Day2.3%4.7%6.3%
1 Year-32.8%-32.8%6.5%5.6%14.7%12.2%
3 Year-25.4%-25.4%13.9%10.3%47.8%38.3%
5 Year-7.5%-7.5%4.7%-0.2%62.1%44.1%

Price Volatility Vs. Market

How volatile is Athersys's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Athersys undervalued compared to its fair value and its price relative to the market?

7.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATHX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ATHX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATHX is overvalued based on its PB Ratio (7.8x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Athersys forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-6.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATHX's revenue is expected to decline over the next 3 years (-117.8% per year).

High Growth Revenue: ATHX's revenue is forecast to decline over the next 3 years (-117.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATHX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Athersys performed over the past 5 years?

-16.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATHX has a high level of non-cash earnings.

Growing Profit Margin: ATHX's current net profit margins (-670.4%) are lower than last year (-108.8%).


Past Earnings Growth Analysis

Earnings Trend: ATHX is unprofitable, and losses have increased over the past 5 years at a rate of -16.3% per year.

Accelerating Growth: Unable to compare ATHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: ATHX has a negative Return on Equity (-170.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Athersys's financial position?


Financial Position Analysis

Short Term Liabilities: ATHX's short term assets ($42.5M) exceeds its short term liabilities ($14.9M)

Long Term Liabilities: ATHX's short term assets (42.5M) exceeds its long term liabilities (5.6M)


Debt to Equity History and Analysis

Debt Level: ATHX is debt free.

Reducing Debt: ATHX has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.


Balance Sheet

Inventory Level: ATHX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ATHX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATHX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ATHX has sufficient cash runway for 1.232029 years if free cash flow continues to reduce at historical rates of -11% each year.


Next Steps

Dividend

What is Athersys's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ATHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ATHX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATHX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Athersys's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average management tenure


CEO

Gil Van Bokkelen (58yo)

24.1yrs

Tenure

US$1,701,622

Compensation

Dr. Gil Van Bokkelen, Ph.D. serves as an Investment Advisor to Early Stage Partners, a venture capital fund based in Ohio. Dr. Van Bokkelen co-founded Athersys, Inc. in October 1995 and has been its Chief  ...


CEO Compensation Analysis

Compensation vs Market: Gil's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Gil's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.7yrs

Average Tenure

55yo

Average Age

Experienced Management: ATHX's management team is considered experienced (3.7 years average tenure).


Board Age and Tenure

15.7yrs

Average Tenure

69yo

Average Age

Experienced Board: ATHX's board of directors are seasoned and experienced ( 15.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.


Management Team

  • Gil Van Bokkelen (58yo)

    Co-Founder

    • Tenure: 24.1yrs
    • Compensation: US$1.70m
  • John Harrington (52yo)

    Co-Founder

    • Tenure: 24.1yrs
    • Compensation: US$1.13m
  • Greg Liposky (64yo)

    Senior VP of Commercial Manufacturing

    • Tenure: 1.3yrs
  • Laura Campbell (55yo)

    Senior Vice President of Finance

    • Tenure: 3.7yrs
    • Compensation: US$677.65k
  • BJ Lehmann (53yo)

    President

    • Tenure: 13.4yrs
    • Compensation: US$1.14m
  • Manal Morsy

    Senior VP & Head of Global Regulatory Affairs

    • Tenure: 6.8yrs
  • Willie Mays

    VP of Regenerative Medicine & Head of Neuroscience Programs

    • Tenure: 3.3yrs
  • Anthony Ting

    VP of Regenerative Medicine & Head of Cardiopulmonary Programs

    • Tenure: 3.3yrs
  • Rakesh Ramachandran

    Head of Information Technology & Communications and VP

    • Tenure: 2.8yrs
  • Karen Hunady

    Director of Corporate Communications & Investor Relations

    • Tenure: 0yrs

Board Members

  • Jeff Randall (75yo)

    Independent Director

    • Tenure: 12.2yrs
    • Compensation: US$153.55k
  • C. Caskey (79yo)

    Scientific and Clinical Advisor

    • Tenure: 0yrs
  • Gil Van Bokkelen (58yo)

    Co-Founder

    • Tenure: 24.1yrs
    • Compensation: US$1.70m
  • Jim Shook (79yo)

    Scientific and Clinical Advisor

    • Tenure: 0yrs
  • John Harrington (52yo)

    Co-Founder

    • Tenure: 24.1yrs
    • Compensation: US$1.13m
  • Lee Babiss (63yo)

    Lead Independent Director

    • Tenure: 6.1yrs
    • Compensation: US$160.05k
  • Ira Mellman

    Scientific and Clinical Advisor

    • Tenure: 0yrs
  • Catherine Verfaillie

    Scientific and Clinical Advisor

    • Tenure: 0yrs
  • Michael Simons

    Scientific and Clinical Advisor

    • Tenure: 0yrs
  • Gilbert Clincke

    Scientific and Clinical Advisor

    • Tenure: 0yrs

Company Information

Athersys, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Athersys, Inc.
  • Ticker: ATHX
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$211.500m
  • Shares outstanding: 156.67m
  • Website: https://www.athersys.com

Number of Employees


Location

  • Athersys, Inc.
  • 3201 Carnegie Avenue
  • Cleveland
  • Ohio
  • 44115
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATHXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2007
4LSDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2007

Biography

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/15 00:06
End of Day Share Price2019/11/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.